C-Rad AB (publ) (LON:0R44)

London flag London · Delayed Price · Currency is GBP · Price in SEK
26.25
+0.25 (0.96%)
At close: Mar 11, 2026
Market Cap69.40M -12.0%
Revenue (ttm)35.62M -5.8%
Net Income846.40K -81.4%
EPS0.02 -81.4%
Shares Outn/a
PE Ratio82.00
Forward PE12.07
Dividendn/a
Ex-Dividend Daten/a
Volume383
Average Volume6,687
Open26.25
Previous Close26.00
Day's Range26.25 - 26.25
52-Week Range26.00 - 35.40
Beta0.80
RSI32.24
Earnings DateMay 6, 2026

About C-Rad AB

C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solution for patient set up and intra-fraction breath hold reproducibility; Catalyst+ PT, a surface image guided radiation therapy solution that supports pr... [Read more]

Industry Electromedical and Electrotherapeutic Apparatus
Founded 2004
Employees 110
Stock Exchange London Stock Exchange
Ticker Symbol 0R44

Financial Performance

In 2025, C-Rad AB's revenue was 441.90 million, a decrease of -5.78% compared to the previous year's 469.00 million. Earnings were 10.50 million, a decrease of -81.40%.

Financial numbers in SEK Financial Statements

News

C-Rad AB (FRA:24C) Q4 2025 Earnings Call Highlights: Navigating Growth and Challenges

C-Rad AB (FRA:24C) Q4 2025 Earnings Call Highlights: Navigating Growth and Challenges

6 weeks ago - GuruFocus

C-Rad AB (FRA:24C) Q3 2025 Earnings Call Highlights: Strong Service Growth Amidst Regional ...

C-Rad AB (FRA:24C) Q3 2025 Earnings Call Highlights: Strong Service Growth Amidst Regional Challenges

5 months ago - GuruFocus